Skip to main content

Advertisement

SpringerLink
Log in

Management of Advanced Small Bowel Cancer

  • Upper Gastrointestinal Cancers (L Rajdev, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Small bower cancer is a rare disease, despite its incidence is increasing in the last decade. Both benign and malignant tumors can arise from the small intestine. The main histological cancer types are adenocarcinomas, neuroendocrine tumors, sarcomas, gastrointestinal stromal tumors (GISTs), and lymphomas. Due to the rarity of these malignances, all the currently available data are based on small studies or retrospective series, although recent breakthroughs are redirecting our approach to these patients. Immunotherapy for small bowel adenocarcinomas, several multikinase inhibitors in resistant GIST patients, as well as everolimus and 177Lu-DOTATATE in neuroendocrine tumors are only few of the novel therapeutic options that have changed, or may change in the future, the therapeutic landscape of these rare cancers. Larger and more powerful studies on the molecular profile of these tumors may lead to a better design of clinical trials, which eventually would provide our patients with more efficacious treatments to improve both overall survival and quality of life.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. https://seer.cancer.gov/statfacts/html/smint.html. SCSFSICNCI.

  2. Bilimoria KY, Bentrem DJ, Wayne JD, Ko CY, Bennett CL, Talamonti MS. Small bowel cancer in the United States: changes in epidemiology, treatment, and survival over the last 20 years. Ann Surg. 2009;249:63–71.

    Article  PubMed  Google Scholar 

  3. Chow JS, Chen CC, Ahsan H, Neugut AI. A population-based study of the incidence of malignant small bowel tumours: SEER, 1973-1990. Int J Epidemiol. 1996;25:722–8.

    Article  CAS  PubMed  Google Scholar 

  4. Severson RK, Schenk M, Gurney JG, et al. Increasing incidence of adenocarcinomas and carcinoid tumors of the small intestine in adults. Cancer Epidemiol Biomark Prev. 1996;5:81–4.

    CAS  Google Scholar 

  5. Hatzaras I, Palesty JA, Abir F, Sullivan P, Kozol RA, Dudrick SJ, et al. Small-bowel tumors: epidemiologic and clinical characteristics of 1260 cases from the Connecticut Tumor Registry. Arch Surg. 2007;142:229–35.

    Article  PubMed  Google Scholar 

  6. Lepage C, Bouvier AM, Manfredi S, Dancourt V, Faivre J. Incidence and management of primary malignant small bowel cancers: a well-defined French population study. Am J Gastroenterol. 2006;101:2826–32.

    Article  PubMed  Google Scholar 

  7. Chow WH, Linet MS, McLaughlin JK, et al. Risk factors for small intestine cancer. Cancer Causes Control. 1993;4:163–9.

    Article  CAS  PubMed  Google Scholar 

  8. Cross AJ, Leitzmann MF, Subar AF, Thompson FE, Hollenbeck AR, Schatzkin A. A prospective study of meat and fat intake in relation to small intestinal cancer. Cancer Res. 2008;68:9274–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Bjorge T, Tretli S, Engeland A. Height and body mass index in relation to cancer of the small intestine in two million Norwegian men and women. Br J Cancer. 2005;93:807–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Boffetta P, Hazelton WD, Chen Y, Sinha R, Inoue M, Gao YT, et al. Body mass, tobacco smoking, alcohol drinking and risk of cancer of the small intestine—a pooled analysis of over 500,000 subjects in the Asia Cohort Consortium. Ann Oncol. 2012;23:1894–8.

    Article  CAS  PubMed  Google Scholar 

  11. Bennett CM, Coleman HG, Veal PG, Cantwell MM, Lau CCL, Murray LJ. Lifestyle factors and small intestine adenocarcinoma risk: a systematic review and meta-analysis. Cancer Epidemiol. 2015;39:265–73.

    Article  PubMed  Google Scholar 

  12. Pan SY, Morrison H. Epidemiology of cancer of the small intestine. World J Gastrointest Oncol. 2011;3:33–42.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Canavan C, Abrams KR, Mayberry J. Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn’s disease. Aliment Pharmacol Ther. 2006;23:1097–104.

    Article  CAS  PubMed  Google Scholar 

  14. Rampertab SD, Forde KA, Green PH. Small bowel neoplasia in coeliac disease. Gut. 2003;52:1211–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Shenoy S. Genetic risks and familial associations of small bowel carcinoma. World J Gastrointest Oncol. 2016;8:509–19.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10.

    Article  CAS  PubMed  Google Scholar 

  17. Aparicio T, Zaanan A, Svrcek M, Laurent-Puig P, Carrere N, Manfredi S, et al. Small bowel adenocarcinoma: epidemiology, risk factors, diagnosis and treatment. Dig Liver Dis. 2014;46:97–104.

    Article  PubMed  Google Scholar 

  18. van Lier MG, Wagner A, Mathus-Vliegen EM, et al. High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258–64 author reply 1265.

    Article  PubMed  Google Scholar 

  19. Hearle N, Schumacher V, Menko FH, Olschwang S, Boardman LA, Gille JJ, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006;12:3209–15.

    Article  CAS  PubMed  Google Scholar 

  20. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000;119:1447–53.

    Article  CAS  PubMed  Google Scholar 

  21. Christie M, Jorissen RN, Mouradov D, Sakthianandeswaren A, Li S, Day F, et al. Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis. Oncogene. 2013;32:4675–82.

    Article  CAS  PubMed  Google Scholar 

  22. Zaaimi Y, Aparicio T, Laurent-Puig P, Taieb J, Zaanan A. Advanced small bowel adenocarcinoma: molecular characteristics and therapeutic perspectives. Clin Res Hepatol Gastroenterol. 2016;40:154–60.

    Article  CAS  PubMed  Google Scholar 

  23. National Comprehensive Cancer Network. Clinical practice guidelines in oncology. Colon Cancer. Version 3.2018. Avalable at: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf. Last Accessed 01 Sept 2018.

  24. • Locher C, Batumona B, Afchain P, et al. Small bowel adenocarcinoma: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Dig Liver Dis. 2018;50:15–9 Updated clinical guidelines for the management of small bowel adenocarcinoma.

    Article  PubMed  Google Scholar 

  25. Faivre J, Trama A, De Angelis R, et al. Incidence, prevalence and survival of patients with rare epithelial digestive cancers diagnosed in Europe in 1995-2002. Eur J Cancer. 2012;48:1417–24.

    Article  CAS  PubMed  Google Scholar 

  26. Nicholl MB, Ahuja V, Conway WC, Vu VD, Sim MS, Singh G. Small bowel adenocarcinoma: understaged and undertreated? Ann Surg Oncol. 2010;17:2728–32.

    Article  PubMed  Google Scholar 

  27. Overman MJ, Hu CY, Wolff RA, Chang GJ. Prognostic value of lymph node evaluation in small bowel adenocarcinoma: analysis of the surveillance, epidemiology, and end results database. Cancer. 2010;116:5374–82.

    Article  PubMed  Google Scholar 

  28. Sakae H, Kanzaki H, Nasu J, Akimoto Y, Matsueda K, Yoshioka M, et al. The characteristics and outcomes of small bowel adenocarcinoma: a multicentre retrospective observational study. Br J Cancer. 2017;117:1607–13.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Ecker BL, McMillan MT, Datta J, et al. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: a propensity score-matched analysis. Cancer. 2016;122:693–701.

    Article  PubMed  Google Scholar 

  30. Ecker BL, McMillan MT, Datta J, et al. Lymph node evaluation and survival after curative-intent resection of duodenal adenocarcinoma: a matched cohort study. Eur J Cancer. 2016;69:135–41.

    Article  CAS  PubMed  Google Scholar 

  31. Dabaja BS, Suki D, Pro B, Bonnen M, Ajani J. Adenocarcinoma of the small bowel: presentation, prognostic factors, and outcome of 217 patients. Cancer. 2004;101:518–26.

    Article  PubMed  Google Scholar 

  32. Halfdanarson TR, McWilliams RR, Donohue JH, Quevedo JF. A single-institution experience with 491 cases of small bowel adenocarcinoma. Am J Surg. 2010;199:797–803.

    Article  PubMed  Google Scholar 

  33. Czaykowski P, Hui D. Chemotherapy in small bowel adenocarcinoma: 10-year experience of the British Columbia Cancer Agency. Clin Oncol (R Coll Radiol). 2007;19:143–9.

    Article  CAS  Google Scholar 

  34. Koo DH, Yun SC, Hong YS, Ryu MH, Lee JL, Chang HM, et al. Systemic chemotherapy for treatment of advanced small bowel adenocarcinoma with prognostic factor analysis: retrospective study. BMC Cancer. 2011;11:205.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Khan K, Peckitt C, Sclafani F, Watkins D, Rao S, Starling N, et al. Prognostic factors and treatment outcomes in patients with small bowel adenocarcinoma (SBA): the Royal Marsden Hospital (RMH) experience. BMC Cancer. 2015;15:15.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Crawley C, Ross P, Norman A, Hill A, Cunningham D. The Royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer. 1998;78:508–10.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Zhang L, Wang LY, Deng YM, Wang FH, Feng F, Chen YC, et al. Efficacy of the FOLFOX/CAPOX regimen for advanced small bowel adenocarcinoma: a three-center study from China. J buon. 2011;16:689–96.

    PubMed  Google Scholar 

  38. Zaanan A, Costes L, Gauthier M, Malka D, Locher C, Mitry E, et al. Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study. Ann Oncol. 2010;21:1786–93.

    Article  CAS  PubMed  Google Scholar 

  39. Locher C, Malka D, Boige V, Lebray P, Elias D, Lasser P, et al. Combination chemotherapy in advanced small bowel adenocarcinoma. Oncology. 2005;69:290–4.

    Article  CAS  PubMed  Google Scholar 

  40. Overman MJ, Kopetz S, Wen S, Hoff PM, Fogelman D, Morris J, et al. Chemotherapy with 5-fluorouracil and a platinum compound improves outcomes in metastatic small bowel adenocarcinoma. Cancer. 2008;113:2038–45.

    Article  CAS  PubMed  Google Scholar 

  41. Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10:132–7.

    Article  CAS  PubMed  Google Scholar 

  42. Tsushima T, Taguri M, Honma Y, Takahashi H, Ueda S, Nishina T, et al. Multicenter retrospective study of 132 patients with unresectable small bowel adenocarcinoma treated with chemotherapy. Oncologist. 2012;17:1163–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Xiang XJ, Liu YW, Zhang L, Qiu F, Yu F, Zhan ZY, et al. A phase II study of modified FOLFOX as first-line chemotherapy in advanced small bowel adenocarcinoma. Anti-Cancer Drugs. 2012;23:561–6.

    Article  CAS  PubMed  Google Scholar 

  44. Horimatsu T, Nakayama N, Moriwaki T, Hirashima Y, Fujita M, Asayama M, et al. A phase II study of 5-fluorouracil/L-leucovorin/oxaliplatin (mFOLFOX6) in Japanese patients with metastatic or unresectable small bowel adenocarcinoma. Int J Clin Oncol. 2017;22:905–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Overman MJ, Varadhachary GR, Kopetz S, Adinin R, Lin E, Morris JS, et al. Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. J Clin Oncol. 2009;27:2598–603.

    Article  CAS  PubMed  Google Scholar 

  46. McWilliams RR, Foster NR, Mahoney MR, et al. North Central Cancer Treatment Group N0543 (Alliance): a phase 2 trial of pharmacogenetic-based dosing of irinotecan, oxaliplatin, and capecitabine as first-line therapy for patients with advanced small bowel adenocarcinoma. Cancer. 2017;123:3494–501.

    Article  CAS  PubMed  Google Scholar 

  47. Zaanan A, Gauthier M, Malka D, Locher C, Gornet JM, Thirot-Bidault A, et al. Second-line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first-line platinum-based chemotherapy: a multicenter AGEO study. Cancer. 2011;117:1422–8.

    Article  CAS  PubMed  Google Scholar 

  48. Overman MJ, Adam L, Raghav K, Wang J, Kee B, Fogelman D, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. Ann Oncol. 2018;29:139–44.

    Article  CAS  PubMed  Google Scholar 

  49. • Schrock AB, Devoe CE, McWilliams R, et al. Genomic profiling of small-bowel adenocarcinoma. JAMA Oncol. 2017;3:1546–53 A large-scale genomic study of small bowel adenocarcinoma samples that provides insights into the molecular profile of this type of cancer.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Hanninen UA, Katainen R, Tanskanen T, et al. Exome-wide somatic mutation characterization of small bowel adenocarcinoma. PLoS Genet. 2018;14:e1007200.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Santini D, Fratto ME, Spoto C, Russo A, Galluzzo S, Zoccoli A, et al. Cetuximab in small bowel adenocarcinoma: a new friend? Br J Cancer. 2010;103:1305 author reply 1306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Falcone R, Roberto M, Filetti M, Anselmi E, Marchetti P. Anti epidermal growth factor receptor therapy in small bowel adenocarcinoma: case report and literature review. Medicine (Baltimore). 2018;97:e9672.

    Article  Google Scholar 

  53. Gulhati P, Raghav K, Shroff R, Varadhachary G, Javle M, Qiao W, et al. Phase II study of panitumumab in RAS wild-type metastatic adenocarcinoma of small bowel or ampulla of Vater. Oncologist. 2018;23:277–e226.

    Article  CAS  PubMed  Google Scholar 

  54. Gulhati P, Raghav K, Shroff RT, Varadhachary GR, Kopetz S, Javle M, et al. Bevacizumab combined with capecitabine and oxaliplatin in patients with advanced adenocarcinoma of the small bowel or ampulla of vater: a single-center, open-label, phase 2 study. Cancer. 2017;123:1011–7.

    Article  CAS  PubMed  Google Scholar 

  55. Thota R, Gonzalez RS, Berlin J, Cardin DB, Shi C. Could the PD-1 pathway be a potential target for treating small intestinal adenocarcinoma? Am J Clin Pathol. 2017;148:208–14.

    Article  PubMed  CAS  Google Scholar 

  56. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409–13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Legué LM, Bernards N, Gerritse SL, van Oudheusden TR, de Hingh IHJT, Creemers GJM, et al. Trends in incidence, treatment and survival of small bowel adenocarcinomas between 1999 and 2013: a population-based study in the Netherlands. Acta Oncol. 2016;55:1183–9.

    Article  PubMed  CAS  Google Scholar 

  58. Rovers KP, de Bree E, Yonemura Y, de Hingh IH. Treatment of peritoneal metastases from small bowel adenocarcinoma. Int J Hyperth. 2017;33:571–8.

    Article  Google Scholar 

  59. Liu Y, Yonemura Y, Levine EA, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal metastases from a small bowel adenocarcinoma: multi-institutional experience. Ann Surg Oncol. 2018;25:1184–92.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Quenet F, Elias D, Roca L, et al. A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. J Clin Oncol. 2018;36(suppl LBA3503). https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA3503.

  61. Howe JR, Karnell LH, Scott-Conner C. Small bowel sarcoma: analysis of survival from the National Cancer Data Base. Ann Surg Oncol. 2001;8(6):496–508.

    Article  CAS  PubMed  Google Scholar 

  62. Talamonti MS, Goetz LH, Rao S, Joehl RJ. Primary cancers of the small bowel: analysis of prognostic factors and results of surgical management. Arch Surg. 2002;137:564–70 discussion 570-561.

    Article  PubMed  Google Scholar 

  63. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–25.

    Article  CAS  PubMed  Google Scholar 

  64. Tran T, Davila JA, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol. 2005;100:162–8.

    Article  PubMed  Google Scholar 

  65. • Poveda A, Garcia Del Muro X, Lopez-Guerrero JA, et al. GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev. 2017;55:107–19 Updated guidelines for the management of GISTs.

    Article  PubMed  Google Scholar 

  66. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279:577–80.

    Article  CAS  PubMed  Google Scholar 

  67. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8:3034–8.

    CAS  PubMed  Google Scholar 

  68. Lenke LG, Engsberg JR, Ross SA, Reitenbach A, Blanke K, Bridwell KH. Prospective dynamic functional evaluation of gait and spinal balance following spinal fusion in adolescent idiopathic scoliosis. Spine (Phila Pa 1976). 2001;26:E330–7.

    Article  CAS  Google Scholar 

  69. Cohen MH, Johnson JR, Justice R, Pazdur R. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors. Oncologist. 2012;17:992–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.

    Article  CAS  PubMed  Google Scholar 

  72. Zalcberg JR, Verweij J, Casali PG, le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41:1751–7.

    Article  CAS  PubMed  Google Scholar 

  73. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329–38.

    Article  CAS  PubMed  Google Scholar 

  74. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:295–302.

    Article  CAS  PubMed  Google Scholar 

  75. Wada R, Arai H, Kure S, Peng WX, Naito Z. “Wild type” GIST: Clinicopathological features and clinical practice. Pathol Int. 2016;66:431–7.

    Article  CAS  PubMed  Google Scholar 

  76. Nishida T. Therapeutic strategies for wild-type gastrointestinal stromal tumor: is it different from KIT or PDGFRA-mutated GISTs? Transl Gastroenterol Hepatol. 2017;2:92.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular subtypes of KIT/PDGFRA wild-type gastrointestinal stromal tumors: a report from the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2:922–8.

    Article  PubMed  PubMed Central  Google Scholar 

  78. Lewis MA, Yao JC. Molecular pathology and genetics of gastrointestinal neuroendocrine tumours. Curr Opin Endocrinol Diabetes Obes. 2014;21:22–7.

    Article  CAS  PubMed  Google Scholar 

  79. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–42.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol. 2017;14:333–42.

    Article  CAS  PubMed  Google Scholar 

  81. Oberg KE. Gastrointestinal neuroendocrine tumors. Ann Oncol. 2010;21(Suppl 7):vii72–80.

    Article  PubMed  Google Scholar 

  82. Sadowski SM, Triponez F. Management of pancreatic neuroendocrine tumors in patients with MEN 1. Gland Surg. 2015;4:63–8.

    PubMed  PubMed Central  Google Scholar 

  83. Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, et al. Association of VHL genotype with pancreatic neuroendocrine tumor phenotype in patients with von Hippel-Lindau disease. JAMA Oncol. 2018;4:124–6.

    Article  PubMed  Google Scholar 

  84. Lodish MB, Stratakis CA. Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab. 2010;24:439–49.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. Rinke A, Muller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009;27:4656–63.

    Article  CAS  PubMed  Google Scholar 

  86. Caplin ME, Pavel M, Cwikla JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

    Article  PubMed  CAS  Google Scholar 

  87. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet. 2011;378:2005–12.

    Article  CAS  PubMed  Google Scholar 

  88. Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77.

    Article  CAS  PubMed  Google Scholar 

  89. Strosberg JR, Weber JM, Feldman M, Coppola D, Meredith K, Kvols LK. Prognostic validity of the American Joint Committee on Cancer staging classification for midgut neuroendocrine tumors. J Clin Oncol. 2013;31:420–5.

    Article  PubMed  Google Scholar 

  90. Kulke MH, Horsch D, Caplin ME, et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J Clin Oncol. 2017;35:14–23.

    Article  CAS  PubMed  Google Scholar 

  91. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Strosberg JR, Halfdanarson TR, Bellizzi AM, Chan JA, Dillon JS, Heaney AP, et al. The North American Neuroendocrine Tumor Society consensus guidelines for surveillance and medical management of midgut neuroendocrine tumors. Pancreas. 2017;46:707–14.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This manuscript was partly supported in part by the National Cancer Institute (grant number P30CA014089), the Gloria Borges WunderGlo Foundation-The Wunder Project, the Dhont Family Foundation, the San Pedro Peninsula Cancer Guild, the Daniel Butler Research Fund, and the Call to Cure Research Fund. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute or the National Institutes of Health.

Author information

Author notes

  1. Alberto Puccini and Francesca Battaglin contributed equally to this work.

Authors and Affiliations

  1. Division of Medical Oncology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue, Suite 3456, Los Angeles, CA, 90033, USA

    Alberto Puccini MD, Francesca Battaglin MD & Heinz-Josef Lenz MD

  2. Department of Medical Oncology, Ospedale Policlinico San Martino, Genoa, Italy

    Alberto Puccini MD

  3. Medical Oncology Unit 1, Clinical and Experimental Oncology Department, Veneto Institute of Oncology IOV-IRCCS, 35128, Padua, Italy

    Francesca Battaglin MD

Authors
  1. Alberto Puccini MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Battaglin MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz-Josef Lenz MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AP and FB drafted the manuscript. H-JL supervised the manuscript. All authors directly provided their contribution, read, and approved the final manuscript.

Corresponding author

Correspondence to Heinz-Josef Lenz MD.

Ethics declarations

Conflict of Interest

Alberto Puccini declares that he has no conflict of interest.

Francesca Battaglin declares that she has no conflict of interest.

Heinz-Josef Lenz has received clinical trial financial support from Merck Serono and Roche and honoraria for advisory board membership and lectures from Bayer, Boehringer Ingelheim, Genentech, Merck Serono, and Roche.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Ethics Approval and Consent to Participate

Not applicable.

Consent for Publication

Not applicable.

Additional information

This article is part of the Topical Collection on Upper Gastrointestinal Cancers

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Puccini, A., Battaglin, F. & Lenz, HJ. Management of Advanced Small Bowel Cancer. Curr. Treat. Options in Oncol. 19, 69 (2018). https://doi.org/10.1007/s11864-018-0592-3

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-018-0592-3

Keywords

Search

Navigation